The SF3B4 gene acrofacial dysostosis 1, Nager type genetic test, is a specialized diagnostic tool designed to identify mutations in the SF3B4 gene, which are linked to acrofacial dysostosis 1, Nager type. This rare genetic disorder is characterized by craniofacial and limb abnormalities, including underdeveloped cheekbones and lower jaw, downward-slanting eyelid openings, absence of lower eyelashes, and malformations of the thumbs and forearms. The test plays a critical role in the early diagnosis and management of the condition, allowing for appropriate genetic counseling and planning for medical care tailored to the individual's needs.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test ensures high accuracy and reliability. The cost of the SF3B4 gene test is set at 4400 AED, reflecting the sophisticated technology and expertise involved in detecting the specific genetic alterations responsible for acrofacial dysostosis 1, Nager type. By opting for this test, patients and their families gain crucial insights into the genetic basis of the condition, enabling informed decisions regarding treatment options and lifestyle adjustments to better manage the associated challenges.
The ATP2A2 gene acrokeratosis verruciformis genetic test is a specialized diagnostic procedure aimed at identifying mutations in the ATP2A2 gene, which are associated with the rare skin disorder known as acrokeratosis verruciformis. This condition is characterized by the development of flat warts, primarily on the hands and feet, and is known to follow an autosomal dominant pattern of inheritance. The test involves analyzing the patient's DNA to detect any genetic abnormalities that may indicate the presence of or predisposition to acrokeratosis verruciformis.
Conducted at DNA Labs UAE, a leading facility in genetic testing, this test is priced at 4400 AED. DNA Labs UAE employs cutting-edge technology and follows stringent protocols to ensure accurate and reliable results. The test is essential for individuals with a family history of the condition or those exhibiting symptoms, as it can provide crucial information for diagnosis, management, and understanding the risk of passing the condition to offspring.
The ARHGAP31 gene plays a crucial role in the development of Adams-Oliver Syndrome Type 1, a rare genetic disorder characterized by the congenital absence of skin (aplasia cutis congenita), malformations of the skull, and limb abnormalities. DNA Labs UAE offers a specialized genetic test designed to identify mutations in the ARHGAP31 gene, which is pivotal for confirming a diagnosis of Adams-Oliver Syndrome Type 1. This targeted testing can provide essential information for affected individuals and their families regarding prognosis, potential treatments, and genetic counseling.
The test, priced at 4400 AED, involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory for specific genetic alterations in the ARHGAP31 gene. Results from this test can help guide clinical management and inform about the risk of passing the condition to future generations. Conducted in a state-of-the-art facility, DNA Labs UAE ensures a high standard of accuracy and reliability for this genetic test, supporting patients and healthcare providers in making informed decisions about care and management of Adams-Oliver Syndrome Type 1.
The "CCDC39 Gene Primary Ciliary Dyskinesia Type 14 Genetic Test" is a specialized diagnostic procedure aimed at identifying mutations in the CCDC39 gene, which are known to cause Primary Ciliary Dyskinesia (PCD) Type 14. This condition is a rare genetic disorder characterized by chronic respiratory tract infections, abnormal organ positioning, and fertility issues, stemming from defects in the action of cilia, the microscopic hair-like structures that line various organs and body parts.
This test is particularly valuable for individuals showing symptoms of PCD or those with a family history of the condition, as it can provide definitive genetic evidence of the disease. The knowledge gained from this test can guide treatment plans, inform family planning decisions, and help with the management of symptoms.
Conducted by DNA Labs UAE, a reputable facility known for its advanced genetic testing services, the test is priced at 4400 AED. The cost reflects the sophisticated technology and expertise required to accurately analyze and interpret the genetic data. For patients and families affected by PCD, this test represents a crucial step towards understanding their condition and accessing appropriate care and support.
The CCDC40 Gene Primary Ciliary Dyskinesia Type 15 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE. Priced at 4400 AED, this test specifically targets the CCDC40 gene to identify mutations that are responsible for Primary Ciliary Dyskinesia (PCD) Type 15. PCD is a rare genetic disorder characterized by chronic respiratory tract infections, abnormal organ positioning, and infertility due to defects in the structure and function of cilia, which are microscopic, hair-like structures that line the airways, reproductive system, and other parts of the body.
The CCDC40 gene plays a crucial role in the proper assembly and function of cilia. Mutations in this gene can disrupt ciliary motion, leading to the symptoms associated with PCD. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to detect any genetic abnormalities in the CCDC40 gene.
Offered at DNA Labs UAE, this genetic test is vital for early diagnosis and management of PCD Type 15. It not only helps in understanding the genetic basis of the condition but also assists in making informed decisions regarding treatment options and family planning. Early diagnosis through this genetic test can significantly improve the quality of life for individuals with PCD Type 15 by allowing for timely interventions and management strategies to alleviate symptoms and prevent complications.
The DNAL1 Gene Primary Ciliary Dyskinesia Type 16 Genetic Test is a specialized diagnostic examination available at DNA Labs UAE, designed to identify mutations in the DNAL1 gene which are associated with Primary Ciliary Dyskinesia (PCD) Type 16. PCD is a rare, inherited disorder that affects the cilia, leading to issues with respiratory function, fertility, and other bodily systems. The test, costing 4400 AED, employs advanced genetic sequencing technologies to analyze the DNAL1 gene, providing essential information for the accurate diagnosis and management of this condition. This genetic test is crucial for individuals with a family history of PCD or those exhibiting symptoms, offering a pathway towards targeted treatment and improved quality of life.
The CCDC103 gene primary ciliary dyskinesia type 17 genetic test is a specialized diagnostic procedure offered at DNA Labs UAE. This test is designed to identify mutations in the CCDC103 gene, which are linked to primary ciliary dyskinesia (PCD) type 17, a rare genetic disorder. PCD is characterized by chronic respiratory tract infections, abnormal organ positioning, and infertility, resulting from defective cilia and flagella mobility. The test, priced at 4400 AED, is crucial for early diagnosis and management of the condition, offering families and individuals critical insights into their genetic health and guiding treatment options.
The DNAAF5 Gene Primary Ciliary Dyskinesia Type 18 Genetic Test is a specialized diagnostic procedure offered at DNA Labs UAE, aimed at detecting mutations in the DNAAF5 gene, which are linked to Primary Ciliary Dyskinesia (PCD) Type 18. PCD is a rare genetic disorder that affects the cilia, tiny hair-like structures that line the airways, reproductive system, and other parts of the body. Mutations in the DNAAF5 gene disrupt the normal function of cilia, leading to a range of symptoms including chronic respiratory infections, fertility issues, and situs inversus. The test, priced at 4400 AED, involves collecting a DNA sample, usually through a blood draw or cheek swab, and analyzing it for specific genetic alterations associated with the condition. This test is crucial for individuals with a family history of PCD or those exhibiting symptoms, as it provides a definitive diagnosis, enabling targeted management and treatment strategies.
The LRRC6 Gene Primary Ciliary Dyskinesia Type 19 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the LRRC6 gene which are associated with Primary Ciliary Dyskinesia (PCD) Type 19. PCD is a rare genetic disorder characterized by chronic respiratory tract infections, abnormal organ positioning, and fertility issues, resulting from defective ciliary structure and function. The LRRC6 gene plays a crucial role in the development and function of cilia, which are microscopic, hair-like structures on the surface of cells, essential for movement and signaling.
This genetic test is pivotal for individuals exhibiting symptoms of PCD, or those with a family history of the condition, as it provides definitive diagnosis by detecting mutations in the LRRC6 gene. Early and accurate diagnosis through this test can significantly improve management and treatment strategies, enhancing the quality of life for affected individuals.
The test is conducted at DNA Labs UAE, a state-of-the-art facility known for its advanced genetic testing capabilities and adherence to international standards. The cost of the LRRC6 Gene Primary Ciliary Dyskinesia Type 19 Genetic Test is 4400 AED, reflecting the comprehensive nature of the analysis and the sophisticated technology employed.
Individuals undergoing this test can expect a simple, non-invasive procedure, typically involving a blood sample or cheek swab, which is then analyzed using cutting-edge genetic sequencing techniques to identify mutations in the LRRC6 gene. Results from this test not only aid in diagnosis but also help in understanding the genetic basis of the condition, facilitating informed decisions regarding family planning for those carrying the gene mutation.
The DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the DNAAF3 gene, which are associated with Primary Ciliary Dyskinesia (PCD) Type 2. PCD is a rare genetic disorder characterized by chronic respiratory tract infections, abnormal organ positioning, and infertility due to defects in the structure and function of cilia, which are microscopic, hair-like structures that line the respiratory tract, middle ear, and other organs.
The DNAAF3 gene plays a crucial role in the development and function of cilia. Mutations in this gene can lead to the improper formation or function of cilia, resulting in the symptoms associated with PCD. By analyzing the DNAAF3 gene, this test can confirm a diagnosis of PCD Type 2, allowing for a better understanding of the condition and enabling targeted management and treatment strategies.
The test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities. The cost of the DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test is 4400 AED. This test is a valuable resource for individuals exhibiting symptoms of PCD or those with a family history of the condition, providing crucial information for managing their health.
